Cargando…

Real-life experience with benralizumab during 6 months

BACKGROUND: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padilla-Galo, A., Levy-Abitbol, RCh, Olveira, C., Valencia Azcona, B., Pérez Morales, M., Rivas-Ruiz, F., Tortajada-Goitia, B., Moya-Carmona, I., Levy-Naon, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325276/ https://www.ncbi.nlm.nih.gov/pubmed/32600318 http://dx.doi.org/10.1186/s12890-020-01220-9

Ejemplares similares

Real-life cost-effectiveness of benralizumab in patients with severe asthma
por: Padilla-Galo, A., et al.
Publicado: (2021)

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
por: Padilla-Galo, Alicia, et al.
Publicado: (2023)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients
por: Padilla-Galo, A., et al.
Publicado: (2018)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022)

Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics
por: Kroes, Johannes A., et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Evaluation of a protocol to detect malnutrition and provide nutritional care for cancer patients undergoing chemotherapy
por: Álvaro Sanz, Elena, et al.
Publicado: (2020)

Impact of a nutrition consultation on the rate of high output stoma-related readmission: an ambispective cohort study
por: Santamaría, Manuela Moreno, et al.
Publicado: (2021)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Socioeconomic Patterns of Twitter User Activity
por: Abitbol, Jacob Levy, et al.
Publicado: (2021)

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
por: Numata, Takanori, et al.
Publicado: (2020)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Benralizumab for severe DRESS in two COVID-19 patients
por: Schmid-Grendelmeier, Peter, et al.
Publicado: (2021)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Aminophylline/benralizumab: Lack of efficacy and eosinopenia: case report
Publicado: (2022)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
por: Magen, Eli, et al.
Publicado: (2022)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
por: BLOMBERG, Maria, et al.
Publicado: (2020)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
por: George, Leena, et al.
Publicado: (2019)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma
por: Mathur, Sameer K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kff217i0inlrfh605usl8m2ha7